HF006
The percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 490 | 537 | 91.2% | |
| HF 4 | 2012 | 499 | 547 | 91.2% | |
| HF 4 | 2013 | 506 | 552 | 91.7% | |
| HF004 | 2014 | 248 | 253 | 98.0% | |
| HF004 | 2015 | 276 | 285 | 96.8% | |
| HF004 | 2016 | 325 | 337 | 96.4% | |
| HF004 | 2017 | 343 | 357 | 96.1% | |
| HF004 | 2018 | 377 | 390 | 96.7% | |
| HF004 | 2019 | 438 | 461 | 95.0% | |
| HF004 | 2020 | 494 | 511 | 96.7% | |
| HF006 | 2021 | 593 | 639 | 92.8% | |
| HF006 | 2022 | 795 | 833 | 95.4% | |
| HF006 | 2023 | 956 | 980 | 97.6% |
